Novartis AG (NVS) FinancialsNVSFinancialNovartis AG

Novartis AG (NVS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Rest of portfolio, accounting for 18.2% of total sales, equivalent to $2.63B. Other significant revenue streams include Immunology - Cosentyx and Oncology -Kisqali. Understanding this composition is critical for investors evaluating how NVS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Novartis AG maintains a gross margin of 75.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 34.51%, while the net margin is 21.79%. These profitability ratios, combined with a Return on Equity (ROE) of 30.55%, provide a clear picture of how effectively NVS converts its operational activities into shareholder value.

In the context of the broader market, NVS competes directly with industry leaders such as AZN and PFE. With a market capitalization of $286.78B, it holds a leading position in the sector. When comparing efficiency, NVS's gross margin of 75.39% stands against AZN's 81.25% and PFE's 67.81%. Such benchmarking helps identify whether Novartis AG is trading at a premium or discount relative to its financial performance.

Novartis has shown solid financials with a gross margin of 75.39% in the latest quarter and a net income of $3.26 billion in Q2 2026. The company reported a year-to-date change of +11.02% and a one-year change of +21.45%, indicating strong performance over the past year.